Google
ZURA — ZURA BIO LIMITED CLASS A ORDINARY SHARES (Healthcare >> Biotechnology)
ZURA FAQ
What is ZURA's ROE?
ZURA BIO LIMITED CLASS A ORDINARY SHARES reports a Return on Equity (ROE) of -34.78%.
What is ZURA's dividend yield?
ZURA BIO LIMITED CLASS A ORDINARY SHARES offers a dividend yield of 0.00%.
What is ZURA's Deepscope Quality Score?
Deepscope rates ZURA's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ZURA?
Deepscope's AI Timing Score for ZURA is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ZURA belong to?
ZURA BIO LIMITED CLASS A ORDINARY SHARES is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.40
Price
-0.27
(-7.36%)
Day Change
|
|
|---|
ZURA, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 85 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.40 |
| PBV / Sector |
1.69 / 4.63
|
| Earning Per Share | -0.70 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
3.58 M
GREAT
|
| Average 1W Daily Value |
5.92 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:20 |
| Symbol | ZURA |
| Name | ZURA BIO LIMITED CLASS A ORDINARY SHARES |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 94.88 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 366.24 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1489 W. Warm Springs Road, Henderson, NV, United States, 89014
Phone: 702 825 9872
Website: https://zurabio.com
Sector: Healthcare >> Biotechnology
Description: Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
